Efficacy and Safety of Rituximab in Children with Refractory Nephrotic Syndrome; A Multicenter Clinical Trial  by Ahn, Yo Han et al.
Selected abstracts from the 34th Annual Spring Meeting of the
Korean Society of Nephrology 2014
Efﬁcacy and Safety of Rituximab in Children with
Refractory Nephrotic Syndrome;
A Multicenter Clinical Trial
Yo Han Ahn 1, Hee Gyung Kang 1, Seong Heon Kim2,
Kyoung Hee Han 3, Hee Yeon Cho 4, Jae Il Shin 5,
Min Hyun Cho 6, Young Seo Park 7, Su Yung Kim 2,
Seung Joo Lee 8, Hae Il Cheong 1, Il-Soo Ha 1
1 Department of Pediatrics, Ewha Womans University School
of Medicine
2 Seoul National University Children's Hospital Department of
Pediatrics, Ewha Womans University School of Medicine
3 Pusan National University Children's Hospital Department of
Pediatrics, Ewha Womans University School of Medicine
4 Jeju National University Hospital Department of Pediatrics,
Ewha Womans University School of Medicine
5 Samsung Medical Center Department of Pediatrics, Ewha
Womans University School of Medicine
6 Severance Children's Hospital Department of Pediatrics,
Ewha Womans University School of Medicine
7 Kyungpook National University Hospital Department of
Pediatrics, Ewha Womans University School of Medicine
8 Asan Medical Center Department of Pediatrics, Ewha
Womans University School of Medicine
Objectives: Rituximab (RTX), anti-CD20 monoclonal antibody,
has been proposed as a rescue therapy for refractory nephrotic
syndrome (NS) on the basis of favorable clinical observations.
While reported efﬁcacy of RTX on refractory RTX is promising,
the long-term effect obtained from randomized clinical trial is
limited, let alone the long-term safety proﬁle of RTX in these
patients. To obtain solid evidence of efﬁcacy and safety of this
medication, we conducted a clinical trial to evaluate the efﬁcacy
and safety of RTX in children with refractory NS. Here we report
the interim result.
Methods: A multicenter open-label trial was performed in
Korean pediatric patients, a single-arm study for steroid and
calcineurin inhibitor (CNI) resistant (resistant NS, RNS), and a
randomized controlled trial for steroid and CNI-dependent NS
(dependent NS, DNS) patients. Eight major centers of
Korea participated in this trial. Patients received a single
dose of intravenous RTX (375 mg/m2) and efﬁcacy was mon-
itored by clinical response and CD19 cell count. Primary end
point was rate of remission achievement for RNS and mainte-
nance of remission for DNS at 6 months after treatment. Steroid
and CNI were slowly tapered as scheduled if remission was
achieved.
Results: Nineteen patients (mean age 9.274.7 years) with RNS
were enrolled and seven patients achieved complete remission
after RTX treatment (remission rate 36.8%). Fifty-three
children (mean age 13.074.9 years) with DNS were included
and randomized to standard treatment or RTX (2:1).
At six months after treatment, the remission rates were 77.1%
in RTX arm (n¼35) and 38.9% in standard therapy arm (n¼18).
The mean durations of remission maintenance were 5.2 months
under slow-tapering standard therapy arm and undetermined
in RTX arm. Twenty four patients (44.4% of 54 patients)
experienced mild and transient infusion reaction during
RTX administration. However, no serious side effect was
observed.
Conclusions: In this interim analysis of clinical trial to evaluate
the efﬁcacy and safety of RTX in children with refractory NS, RTX
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treatment for refractory NS was safe and effective, especially in
patients with DNS.
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Background: Highly sensitized (HS) patients seldom have
chance to receive kidney transplant. To increase transplantation
rate among those population, previous IV immunoglobulin and
rituximab desensitization protocol showed good transplant con-
version rate, but also carried moderate rate of antibody mediated
rejection. Bortezomib, a proteasome inhibitor can control the
production of anti-HLA antibodies through plasma cell apoptosis.
A single center waitlist desensitization programwas employed to
facilitate successful kidney transplantation in HS patients group.
Methods: We prospectively enrolled 23 patients from Jul 2010
to Dec 2013. Desensitization protocol included two doses of IVIG
(2 g/kg), single dose of rituximab (375 mg/m2, max 500 mg), and
4 days of bortezomib (1.3 mg/m2 on days 1,3,7 and 9). Anti-HLA
class I and II antibodies were determined by Luminex solid phase
bead assay at baseline and M2, M3 and M6. We investigated the
difference of transplant conversion rate between desensitized HS
patients and non-desensitized HS waitlist patients. Also we
analyzed the difference of PRA % values and mean ﬂuorescence
intensity (MFI) between pre- and post-desensitization serum.
Results: Mean age of treatment group was 48.7711.2 years old.
Male to female ratio was 12:11. Oþ blood type patients were
34.8% of patients. Mean duration of previous renal replacement
therapy were 153.5765.5 months. Baseline mean class I and II
PRA % values were 86715.3 and 66734. Baseline class I and II
MFI values were 13,89376,147 and 12,27476,891. After desen-
sitization, kidney transplant were successfully performed in
34.8% of patients, compared to 13.8% transplant conversion rate
among non-desentized HS controls (p¼0.001 by Log-Rank).
Among KT recipients, median duration of waiting after desensi-
tization was 3 months with interquartile range 2-8.1 months.
Class I PRA % had showed decreased values until 3 months after
desensitization. After 6 months, there were no differences
between the class I PRA values between pre-desensitization
samples and post-desensitization samples. There were no other
differences except class I PRA % values. Desensitization protocol
were generally well tolerated, with the completion rate of 92%
patients. There were no serious adverse events, but moderate
adverse event were in 46%, most commonly fever and diarrhea.
Conclusion: Highly sensitized waitlist patients are manageable
by desensitization protocol including bortezomib.
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Background: While combination therapy of Rituximab (RTX)
and intravenous immunoglobulin (IVIg) (RIT) has been proposed
as therapeutic strategy for the treatment of chronic active
antibody-mediated rejection (CAMR), its efﬁcacy has not been
established. In this study, we compared clinical outcome
between the treatment group and historic control group to
ascertain the efﬁcacy of combination therapy for CAMR.
Methods: Fifty-four patients diagnosed as CAMR from 2003 to
2013 were included in this study, among whom twenty-ﬁve
were treated with RTX (375 mg/m2) and IVIg (0.4 g/kg) for 4 days
(RIT group) and the remaining twenty-nine patients were
regarded as historic control group. We assessed the change of
allograft function before and after the diagnosis of CAMR in
terms of the amount of decline in estimated glomerular ﬁltration
rate per month (ΔeGFR) and also investigated allograft survival
rate after diagnosis of CAMR.
Results: Neither of the two groups showed any signiﬁcant differ-
ences with respect to clinical, historical and baseline characteristics
including age at biopsy and gender. Nor did they show any
remarkable differences on ΔeGFR and eGFR prior to and at the time
of biopsy. However, ΔeGFR improved signiﬁcantly to 0.027
1.3 mLdmin-1d1.73m-2 per month 6 months after biopsy compared
to that observed 6months before RIT (1.3371.21, po0.05). Hence,Δ
eGFR post-Bx was signiﬁcantly lower in treatment group compared
to that of historic control group. Moreover allograft survival rate after
biopsy was signiﬁcantly higher in treatment group at 3 years from
the diagnosis of CAMR.
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